DUBLIN, IRELAND -- (Marketwired) -- 02/13/15 -- Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today announced it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ACTIMMUNE in the treatment of Friedreich's Ataxia (FA). The Company has simultaneously requested Fast Track Designation.

Read More: Horizon Pharma plc Submits Investigational New Drug Application for ACTIMMUNE(R) in the Treatment of Friedreich's Ataxia